PALIVIZUMAB IMUNOPROTECTION AGAINST SEVERE INFECTIONS CAUSED BY RESPIRATORY SYNCYTIAL VIRUS
Keywords:
preterm, RSV, preventionAbstract
Respiratory Syncytial Virus (RSV) is most common cause of upper airways infection as well as acute bronchiolitis in infants. RSV leads to severe airway disease in high risk infants particularly during winter season. Since there is no appropriate vaccine against RSV , the passive immunization, imunoprofilaxis has been introduced .Palivizumab profilaxis is an expensive option. The cost benefit ratio predicts that five consecutive dosages in high risk infants in epidemic season will provide an optimal balance. Imunoprofilaxis is recommended and carried out by specialized pediatric professionals according world recognized guidelines. Rapid RSV testing detects the presence of respiratory syncytial virus in nasal secretions to help diagnose the infection.
References
American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospital¬ization for respiratory syncytial virus infection. Pediatrics. 2014; 134:e620- 38.
Synagis (palivizumab) package insert. Gaithersburg, MD: MedImmune; 2014 Mar.
American Academy of Pediatrics Committee on Infectious Diseases. Red book: 2012 report of the Com¬mittee on Infectious Diseases. https://redbook.solutions.aap.org/ DocumentLibrary/RB12_interior.pdf (accessed 2016 Oct 6).
American Academy of Pediatrics Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014; 134:415-20. Erratum, Pediatrics. 2014; 134:1221.
Synagis Prescribing Information. Gaithersburg, MD: MedImmune, LLC; May 2017. Available at https://www.azpicentral.com/synagis/synagis.pdf page1. Accessed February 8, 2019.
Policy Statement: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Pediatrics. August 2014; 134(2): e415-20. doi: 10.1542/peds.2014-1665.
Technical Report: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Pediatrics. August 2014; 134(2): e620-38. doi: 10.1542/peds.2014-1666.
Errata: RSV Policy Statement: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. American Academy of Pediatrics. Pediatrics. December 2014; 134(6): 1221.
Respiratory syncytial virus infection (RSV): Trends and surveillance. Centers for Disease Control and Prevention website. Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Available at http://www.cdc.gov/rsv/ research /us-surveillance.html. Page last reviewed: June 26, 2018. Accessed February 8.
Miller EK, Gebretsadik T, Carroll KN, et al. Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatr Infect Dis J. 2013;32(9):950–955pmid:23694832.
Meissner HC, Kimberlin DW. RSV immunoprophylaxis: does the benefit justify the cost? Pediatrics. 2013;132(5): 915918pmid:24127478.
Stempel HE, Martin ET, Kuypers J, Englund JA, Zerr DM. Multiple viral respiratory pathogens in children with bronchiolitis. Acta Paediatr. 2009;98(1): 123–126 pmid:18785966.
